NCT01600222 - Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Psoriasis Vulgaris

Interventions

DRUG

LEO 90100

Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)

Trial Locations (10)

Guildford Dermatology Specialists, Surrey

PerCuro Clinical Research, Victoria

Winnipeg Clinic Dermatology Research, Winnipeg

Maritime Medical Research Center, Bathurst

Ultranova Skincare, Barrie

Co-Medica, Courtice

Mediprobe Research, London

The Centre for Dermatology, Richmond Hill

K. Papp Clinical Research, Waterloo

Centre de Dermatologie Maizerets, Québec